.png)
Erlonat 100 mg: Erlotinib Uses and Side Effects
Erlonat 100 mg is a prescription anticancer medicine containing erlotinib, a targeted therapy used for certain types of lung and pancreatic cancer. Unlike traditional chemotherapy, erlotinib targets a specific protein involved in cancer cell growth. It is particularly relevant for selected patients with non-small cell lung cancer (NSCLC) who have specific genetic changes. However, Erlonat is not suitable for every cancer patient, and treatment requires careful medical supervision. Side effects such as skin rash, diarrhoea, and fatigue are relatively common, while serious complications can occasionally occur. This guide explains Erlonat 100 mg uses, how it works, administration precautions, possible side effects, and important safety information.
What Is Erlonat 100 mg?
Erlonat 100 mg is an oral anticancer tablet containing 100 mg of erlotinib, supplied as erlotinib hydrochloride. It is manufactured by Natco Pharma in India.
The Natco Pharma Erlonat product listing identifies Erlonat tablets in 100 mg and 150 mg strengths.
Erlotinib belongs to a class of medicines called tyrosine kinase inhibitors (TKIs).
These medicines target particular signals that cancer cells use to grow and multiply.
Is Erlonat Chemotherapy?
Erlonat is classified as targeted cancer therapy rather than conventional cytotoxic chemotherapy.
Traditional chemotherapy affects rapidly dividing cells throughout the body. Erlotinib specifically blocks signalling through a protein called epidermal growth factor receptor (EGFR).
However, targeted treatment can still cause significant side effects and requires monitoring.
What Is Erlonat 100 mg Used For?
Erlonat contains erlotinib, which has established medical uses in selected non-small cell lung cancers and advanced pancreatic cancer.
Treatment suitability depends on the diagnosis, cancer stage, genetic test results, and previous therapies.
Non-Small Cell Lung Cancer
NSCLC is the most common broad category of lung cancer.
Some NSCLC tumours contain changes in the EGFR gene that encourage cancer cells to grow.
Erlotinib is used for selected advanced or metastatic NSCLC with certain EGFR mutations, particularly exon 19 deletions or exon 21 L858R substitutions.
EGFR mutation testing helps doctors identify patients who may benefit.
However, other EGFR-targeted medicines are available, and erlotinib is not automatically the preferred option for every patient.
Advanced Pancreatic Cancer
Erlotinib may also be used with gemcitabine, a chemotherapy medicine, for locally advanced, unresectable, or metastatic pancreatic cancer.
The National Cancer Institute's erlotinib drug summary describes these established uses.
Treatment selection depends on the person's overall health, disease characteristics, and available alternatives.
Established erlotinib uses and important treatment considerations.
Cancer Type | Role of Erlotinib | Important Consideration |
EGFR-mutated advanced NSCLC | Targeted cancer therapy | Genetic testing is important |
Advanced pancreatic cancer | Used with gemcitabine | Combination treatment is required |
NSCLC without relevant EGFR mutations | Not a current US-approved use | Other treatments are considered |
Other cancer types | Investigational or selected off-label use | Requires specialist assessment |
How Does Erlotinib Work Against Cancer?
Erlotinib blocks the activity of EGFR, a protein found on the surface of certain cells.
EGFR normally helps regulate cell growth and survival.
In some cancers, abnormal EGFR signalling allows tumour cells to multiply excessively.
By blocking this signal, erlotinib may slow cancer growth or reduce tumour size in appropriately selected patients.
Does Erlotinib Cure Cancer?
Erlotinib is not considered a guaranteed cure for advanced cancer.
Its main purpose is to help control disease in patients whose tumours are likely to respond.
Some patients experience meaningful disease control, while others may have limited benefit.
Cancer cells can also develop resistance, meaning treatment becomes less effective over time.
Doctors monitor treatment response through imaging, symptoms, laboratory tests, and overall health.
Erlonat 100 mg is not suitable for every lung cancer patient. EGFR mutation testing and specialist assessment are essential because the effectiveness of targeted therapy depends heavily on the cancer's biological characteristics.
How Should Erlonat 100 mg Be Taken?
Erlonat should be taken exactly as prescribed by an oncologist.
Erlotinib tablets are generally taken on an empty stomach, at least one hour before or two hours after eating.
Food can increase erlotinib absorption and potentially affect medicine exposure.
Does Every Patient Take 100 mg?
No. The prescribed strength depends on the cancer type, treatment plan, and individual circumstances.
Under US erlotinib prescribing information, the usual starting dose is 150 mg daily for eligible NSCLC patients and 100 mg daily with gemcitabine for pancreatic cancer.
Doctors may adjust treatment when necessary because of side effects or other medical factors.
The official erlotinib tablet prescribing information explains these differences.
Important Administration Precautions
Swallow tablets with water according to your prescription.
Take the medicine consistently at the recommended time.
Do not crush or change the tablet without pharmacist guidance.
Avoid grapefruit and grapefruit juice.
Do not double the next dose if one is missed.
Never increase, reduce, or stop treatment independently.
Treatment duration depends on effectiveness, tolerability, and your oncologist's recommendations.
What Are the Side Effects of Erlonat 100 mg?
Like other cancer medicines, erlotinib can cause side effects.
The most commonly reported problems include skin rash and diarrhoea.
Skin Rash and Dryness
Erlotinib may cause an acne-like rash, particularly on the face, chest, and back.
Dryness, itching, and skin sensitivity may also occur.
Use gentle skincare products and protect your skin from excessive sunlight.
Do not assume that severe rash indicates better cancer treatment results.
Diarrhoea and Digestive Problems
Diarrhoea, nausea, reduced appetite, and mouth discomfort may develop during treatment.
Persistent diarrhoea can cause dehydration and electrolyte imbalance.
Contact your cancer care team if bowel symptoms become frequent, severe, or difficult to manage.
Fatigue and Other Symptoms
Some patients experience tiredness, weakness, headache, or changes in appetite.
These symptoms may result from treatment, cancer itself, or other medical conditions.
Erlotinib side effects and when medical assessment is needed.
Side Effect | Possible Severity | Recommended Action |
Mild skin rash | Common | Discuss skincare with the oncology team |
Mild diarrhoea | Common | Follow hydration and treatment advice |
Persistent vomiting | Potentially serious | Contact the healthcare team promptly |
New breathing difficulty | Serious | Seek urgent medical assessment |
Severe blistering rash | Serious | Obtain immediate medical advice |
Eye pain or vision changes | Potentially serious | Seek prompt medical assessment |
What Precautions Matter During Erlonat Treatment?
Erlotinib can interact with other medicines and requires ongoing medical supervision.
Medicine Interactions
Certain acid-reducing medicines, including omeprazole and other proton pump inhibitors, can lower erlotinib absorption.
Some antibiotics, antifungal medicines, and herbal products may also affect erlotinib levels.
Warfarin users may require additional blood-clotting monitoring.
The MedlinePlus erlotinib safety guidance recommends reviewing all prescription medicines, supplements, and herbal products with a healthcare professional.
Smoking can also reduce erlotinib exposure. Tell your oncologist if you smoke rather than changing treatment yourself.
Pregnancy and Breastfeeding
Erlotinib may harm an unborn baby.
Patients who could become pregnant should discuss effective contraception during treatment and for at least one month after the final dose.
Breastfeeding is not recommended during treatment or for two weeks after the final dose.
Treatment Monitoring
Doctors may monitor liver function, kidney function, blood counts when appropriate, and treatment response.
Report worsening symptoms rather than waiting until your next scheduled appointment.
When Should You Seek Immediate Medical Attention?
Serious reactions to erlotinib are less common but can be dangerous.
Seek urgent medical assessment for:
New or worsening breathlessness, cough, or fever
Severe or persistent diarrhoea with dehydration
Blistering or peeling skin
Significant eye pain or sudden vision changes
Yellowing of the eyes or skin
Severe abdominal pain
New breathing symptoms can occasionally indicate interstitial lung disease, a potentially serious inflammatory lung reaction.
Severe liver injury and gastrointestinal perforation are also recognised risks.
Chest pain, severe breathing difficulty, collapse, or signs of stroke require emergency medical care.
Conclusion
Erlonat 100 mg contains erlotinib, a targeted anticancer medicine used for selected lung cancers and, with gemcitabine, advanced pancreatic cancer. Its effectiveness depends on the cancer type, molecular characteristics, and individual treatment plan. Although erlotinib can help control certain cancers, common side effects include rash, diarrhoea, fatigue, and digestive discomfort. Serious lung, liver, skin, or eye complications require prompt medical attention.
If you have been prescribed Erlonat 100 mg, follow your oncologist's instructions carefully, report new symptoms, and attend regular treatment reviews. Never change the prescribed dose or discontinue cancer therapy without professional guidance.
Frequently Asked Questions
1. What is Erlonat 100 mg used for?
Erlonat 100 mg contains erlotinib, a targeted anticancer medicine used for selected advanced lung cancers and, with gemcitabine, advanced pancreatic cancer. Treatment suitability depends on the diagnosis, molecular test results, and specialist assessment.
2. Is Erlonat 100 mg chemotherapy?
Erlonat is classified as targeted therapy rather than traditional chemotherapy. It blocks EGFR signalling involved in cancer cell growth. However, it can still cause significant side effects and requires regular medical monitoring.
3. What are the common side effects of Erlonat 100 mg?
Common side effects include skin rash, diarrhoea, nausea, fatigue, and reduced appetite. Serious reactions involving the lungs, liver, eyes, or skin are less common. Report persistent or worsening symptoms promptly.
4. Should Erlonat 100 mg be taken before food?
Yes. Erlotinib is generally taken on an empty stomach, at least one hour before or two hours after eating. Food can change its absorption. Follow your oncologist's prescribed schedule.
5. Can Erlonat 100 mg cure lung cancer?
Erlotinib may help control selected EGFR-mutated lung cancers, but it does not guarantee a cure. Response varies according to tumour characteristics and other factors. Regular assessments help determine whether treatment is working.
6. Can I stop Erlonat if my side effects improve or worsen?
Do not stop or change treatment independently. Your oncologist may adjust the dose or interrupt treatment when medically necessary. Seek immediate assessment for severe breathing problems, serious skin reactions, or other warning signs.
Comments